1. Home
  2. WING vs NUVL Comparison

WING vs NUVL Comparison

Compare WING & NUVL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Wingstop Inc.

WING

Wingstop Inc.

HOLD

Current Price

$265.12

Market Cap

6.7B

ML Signal

HOLD

Logo Nuvalent Inc.

NUVL

Nuvalent Inc.

HOLD

Current Price

$103.39

Market Cap

7.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
WING
NUVL
Founded
1994
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Restaurants
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.7B
7.1B
IPO Year
2015
2021

Fundamental Metrics

Financial Performance
Metric
WING
NUVL
Price
$265.12
$103.39
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
26
15
Target Price
$342.12
$135.00
AVG Volume (30 Days)
559.1K
588.5K
Earning Date
02-18-2026
02-26-2026
Dividend Yield
0.45%
N/A
EPS Growth
79.44
N/A
EPS
6.14
N/A
Revenue
$682,980,000.00
N/A
Revenue This Year
$13.82
N/A
Revenue Next Year
$17.53
N/A
P/E Ratio
$43.25
N/A
Revenue Growth
15.55
N/A
52 Week Low
$204.00
$55.54
52 Week High
$388.14
$113.02

Technical Indicators

Market Signals
Indicator
WING
NUVL
Relative Strength Index (RSI) 49.89 48.27
Support Level $259.00 $100.19
Resistance Level $282.00 $107.51
Average True Range (ATR) 13.70 4.89
MACD -0.93 -0.41
Stochastic Oscillator 31.18 36.14

Price Performance

Historical Comparison
WING
NUVL

About WING Wingstop Inc.

Founded in 1994 in Garland, Texas, Wingstop is a restaurant operator specializing in indulgent bone-in and boneless chicken wings, chicken tenders, fries, and, recently, chicken sandwiches. The firm's footprint has grown quickly since its inception, expanding to 2,932 global stores at the end of the third quarter of 2025. With a 98% franchised model, Wingstop generates the lion's share of its revenue from franchise royalties and advertising fees, with the remainder derived from a small footprint of company-owned stores.

About NUVL Nuvalent Inc.

Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.

Share on Social Networks: